Lifeward Ltd. (Nasdaq: LFWD) 2025 Annual Report — Key Investor Takeaways

Executive Summary

Lifeward Ltd., formerly known as ReWalk Robotics Ltd., has released its annual report for the fiscal year ended December 31, 2025. The company, an Israel-based medical device innovator, specializes in designing, developing, and commercializing advanced rehabilitation and mobility solutions, including the ReWalk Personal Exoskeleton, AlterG Anti-Gravity systems, and MyoCycle FES cycles.

Key Points from the Annual Report

• Going Concern Warning: Lifeward Ltd. has concluded there is substantial doubt about its ability to continue as a going concern. This is a critical red flag for shareholders and could have a significant impact on the share price if the company is unable to secure additional funding or improve its financial position.
• Liquidity and Capital Needs: The company warns that it may not have sufficient funds to meet future operating needs or capital requirements. Management may consider further capital-raising transactions, including equity or debt financings, strategic partnerships, or borrowings. Any such moves could dilute existing shareholders or introduce restrictive covenants.
• Recent Reverse Share Splits: Lifeward executed a 1-for-7 reverse share split on March 15, 2024, and a subsequent 1-for-12 reverse share split on February 24, 2026, to maintain compliance with Nasdaq listing requirements. All share and per-share figures have been retroactively adjusted to reflect these splits.
• Nasdaq Listing Compliance: The company highlights the risk of delisting from the Nasdaq Capital Market if it fails to maintain compliance with continued listing requirements. Delisting could severely impact share liquidity and access to capital.
• Public Float and Shares Outstanding: As of June 30, 2025, the public float was approximately \$9.97 million. As of March 17, 2026, Lifeward had 628,222 ordinary shares outstanding.
• Revenue Concentration: Lifeward’s revenue relies heavily on sales of the ReWalk Personal Exoskeleton, AlterG systems, MyoCycle products, and related services and consumables. Failure to achieve or maintain market acceptance of these products could materially impact future revenues.
• Regulatory and Reimbursement Risks: The company’s growth depends on achieving reimbursement from third-party payors, including private insurance, government programs, and Medicare/Medicaid. Inability to secure or maintain coverage could impact profitability.
• Cost Reduction and Operational Restructuring: Management has implemented cost reduction initiatives, including the transition to in-house manufacturing for ReWalk products. However, there is no guarantee the company will realize the anticipated benefits or operational efficiencies.
• Geopolitical and Market Risks: Lifeward faces enhanced economic and political risks, particularly due to geopolitical tensions in Taiwan/China and Russia. Global instability, inflation, and supply chain disruptions are also cited as potential threats to operations and financial condition.
• Product and Regulatory Risks: Any defects in the company’s devices or software, failure to comply with FDA or other regulatory requirements, or inability to gain/maintain regulatory approvals could lead to product recalls, enforcement actions, and loss of market access.
• Cybersecurity: The company notes heightened risk of cyberattacks or IT system incidents that could disrupt business operations—a factor that could materially impact financial results and reputation.
• Acquisition and Integration Risk: Lifeward may seek to grow through acquisitions or strategic alliances. Failure to integrate new businesses or technologies could create additional risks.
• Shareholder Activism: The company acknowledges the potential impact of activist shareholders, which could be disruptive, costly, and affect the trading value of its securities.
• Legal Structure and Jurisdiction: Lifeward is organized under the laws of Israel. Shareholders’ rights differ from those of U.S.-domiciled companies.
• Access to Information: The company’s filings, including this annual report, are available on its website and via the SEC’s EDGAR system.

Potential Price Sensitive Issues for Shareholders

• “Substantial Doubt” Going Concern Statement: This is a strong signal of financial distress and may provoke negative market reactions and increased volatility.
• Possible Dilution or Debt Financing: Management is considering raising additional capital, which may dilute existing shareholders or burden the company with debt.
• Nasdaq Listing at Risk: Failure to maintain compliance could lead to delisting, reducing liquidity and institutional interest.
• Reverse Share Splits: These may be perceived as negative signals and could impact investor sentiment.
• Regulatory and Market Access Risks: Any adverse regulatory decisions, especially regarding reimbursement, could materially impact future sales and profitability.
• Geopolitical Tensions: Exposure to global instability and reliance on international markets add uncertainty to revenue forecasts and supply chain stability.

Company Overview

Lifeward Ltd. is a medical device company focused on innovative rehabilitation and mobility technologies. Its ReWalk Personal Exoskeleton is a leading product for individuals with spinal cord injuries, complemented by the AlterG Anti-Gravity system and MyoCycle FES cycles. The company continues to pursue regulatory approvals and market expansion in additional jurisdictions.

Principal executive offices are at 2 Cabot Rd., Hudson, MA 01749, with a contact number of (508) 251-1154. The company’s website is golifeward.com.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisor before making any investment decisions. The information summarized herein is based on the company’s publicly filed annual report and may be subject to changes or updates. Past performance is not indicative of future results.

View Lifeward Ltd. Historical chart here